Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) CEO Randall C. Schatzman sold 8,181 shares of the stock in a transaction dated Monday, October 3rd. The shares were sold at an average price of $31.15, for a total transaction of $254,838.15. Following the completion of the sale, the chief executive officer now owns 122,949 shares of the company’s stock, valued at approximately $3,829,861.35. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) traded up 1.25% on Wednesday, hitting $31.47. 296,316 shares of the stock were exchanged. Alder BioPharmaceuticals Inc. has a 12 month low of $15.82 and a 12 month high of $39.43. The stock’s market cap is $1.58 billion. The company has a 50-day moving average of $32.29 and a 200-day moving average of $28.37.
Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings data on Tuesday, July 26th. The biopharmaceutical company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.75) by $0.04. The company had revenue of $0.11 million for the quarter, compared to analyst estimates of $1.14 million. During the same quarter in the prior year, the firm earned ($0.46) earnings per share. Alder BioPharmaceuticals’s quarterly revenue was up 112900.0% compared to the same quarter last year. On average, equities analysts predict that Alder BioPharmaceuticals Inc. will post ($3.33) EPS for the current year.
Large investors have recently bought and sold shares of the company. Norges Bank acquired a new stake in Alder BioPharmaceuticals during the fourth quarter valued at approximately $10,183,000. Prudential Financial Inc. raised its stake in Alder BioPharmaceuticals by 12.5% in the first quarter. Prudential Financial Inc. now owns 104,100 shares of the biopharmaceutical company’s stock valued at $2,549,000 after buying an additional 11,600 shares during the last quarter. BlackRock Fund Advisors raised its stake in Alder BioPharmaceuticals by 4.2% in the first quarter. BlackRock Fund Advisors now owns 1,136,823 shares of the biopharmaceutical company’s stock valued at $27,841,000 after buying an additional 45,908 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Alder BioPharmaceuticals by 11.4% in the first quarter. JPMorgan Chase & Co. now owns 349,482 shares of the biopharmaceutical company’s stock valued at $8,559,000 after buying an additional 35,883 shares during the last quarter. Finally, State Street Corp raised its stake in Alder BioPharmaceuticals by 20.2% in the first quarter. State Street Corp now owns 1,195,800 shares of the biopharmaceutical company’s stock valued at $29,282,000 after buying an additional 200,566 shares during the last quarter.
Several equities research analysts have commented on ALDR shares. Brean Capital started coverage on shares of Alder BioPharmaceuticals in a research note on Friday, September 30th. They issued a “buy” rating and a $45.00 price objective for the company. JPMorgan Chase & Co. started coverage on shares of Alder BioPharmaceuticals in a research note on Tuesday, September 13th. They issued an “overweight” rating and a $40.00 price objective for the company. Jefferies Group reiterated a “buy” rating and issued a $61.00 price objective on shares of Alder BioPharmaceuticals in a research note on Thursday, June 9th. Finally, Zacks Investment Research upgraded shares of Alder BioPharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, July 6th. Seven analysts have rated the stock with a buy rating, Alder BioPharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $45.00.
About Alder BioPharmaceuticals
Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.
Receive News & Ratings for Alder BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.